Sierra Oncology Announces Submission Of New Drug Application For Momelotinib To US FDA
$SRRA
Biotechnology: Pharmaceutical Preparations
Health Care
Sierra Oncology Announces Submission Of New Drug Application For Momelotinib To US FDA
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/31/2022 | $35.00 → $51.00 | Buy | HC Wainwright & Co. |
| 11/30/2021 | $33.00 → $39.00 | Overweight | Cantor Fitzgerald |
| 11/5/2021 | $29.00 → $35.00 | Buy | HC Wainwright & Co. |
| 9/27/2021 | $33.00 | Overweight | Cantor Fitzgerald |
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib, an ACVR1 / ALK2, JAK1 and JAK2 inhibitor in development for the treatment of myelofibrosis. "Today is truly momentous for everyone at Sierra Oncology and the patients we serve. This team designed a targeted study to address the highest unmet need and delivered incredible results in the midst of a pandemic. We are thrilled to submit this ND
– Oral presentation of MOMENTUM pivotal phase 3 data in myelofibrosis patients who are symptomatic and anemic – – Poster presentation to highlight improved transfusion independence, symptoms and spleen volume of these myelofibrosis patients who also present with thrombocytopenia – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association (EHA). An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemi
4 - Sierra Oncology, Inc. (0001290149) (Issuer)
4 - Sierra Oncology, Inc. (0001290149) (Issuer)
4 - Sierra Oncology, Inc. (0001290149) (Issuer)
15-12G - Sierra Oncology, Inc. (0001290149) (Filer)
EFFECT - Sierra Oncology, Inc. (0001290149) (Filer)
EFFECT - Sierra Oncology, Inc. (0001290149) (Filer)
HC Wainwright & Co. reiterated coverage of Sierra Oncology with a rating of Buy and set a new price target of $51.00 from $35.00 previously
Cantor Fitzgerald reiterated coverage of Sierra Oncology with a rating of Overweight and set a new price target of $39.00 from $33.00 previously
HC Wainwright & Co. reiterated coverage of Sierra Oncology with a rating of Buy and set a new price target of $35.00 from $29.00 previously
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad
RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, appointed Angie You, Ph.D., to its board of directors. Dr. You is a seasoned biotechnology executive and was recently the chief executive officer of Amunix Pharmaceuticals, Inc., where she orchestrated the sale of the Company to Sanofi for over $1.2 billion. She also serves on the board of ORIC Pharmaceuticals, Inc. "RayzeBio is at the forefront of advancing the targeted radiopharmaceuticals modality to development treatment solutions for unmet medical need in solid tumor indications. I have known Ken for over 20 years and am excited to partner with him, the Rayze
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You currently serves as chief executive officer of Amunix Pharmaceuticals, Inc. "We are delighted to welcome Angie to ORIC's board of directors," said Jacob Chacko, M.D., president and chief executive officer. "Angie's broad experience spanning venture capital, a variety of business development transactions, and public company leadership will bring valuable expertise and in
—New Drug Application submission planned for second quarter of 2022— —Full data set to be presented at an upcoming medical meeting— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced positive topline data from the pivotal Phase 3 MOMENTUM study—a global, randomized, double-blind clinical trial evaluating momelotinib (MMB) in myelofibrosis patients who are symptomatic and anemic and previously treated with an approved JAK inhibitor. The trial met all of its primary and key secondary endpoints. "These data are extremely exciting and everything we had hoped to see from the trial," said Step
—Combination study to build upon momelotinib's differentiated potential as a cornerstone myelofibrosis therapy-— Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it has acquired an exclusive global license from AstraZeneca (NASDAQ:AZN) for AZD5153, a potent and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study examining momelotinib in combination with AZD5153 in myelofibrosis patients in the first half of 2022. "This global in-licensing deal is of two-fold importance to Sierra's long-term strategy. First, it brings
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decade. Mr. Nicols will remain on Codexis' Board through the ann
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Addex Stops Parkinson's-Associated Dyskinesia Trial Addex Therapeutics Ltd (NASDAQ:ADXN) has terminated the Phase 2b/3 study of dipraglurant for dyskinesia associated with Parkinson's disease (PD-LID) due to slow recruitment of patients. The company plans to advance its preclinical portfolio toward the clinic and pursue strategic collaborations for selected programs. Shares were down 52.47% at $1.59 Friday morning. Rhythm's Setmelanotide Scores FDA Approval For Expanded Use In Bardet-Biedl Syndrome The FDA approved Rhythm Pharmaceuticals Inc's (NASDAQ:RYTM) Imcivree (setmelanotide), a me
SC 13D/A - Sierra Oncology, Inc. (0001290149) (Subject)
SC 13G/A - Sierra Oncology, Inc. (0001290149) (Subject)
SC 13D/A - Sierra Oncology, Inc. (0001290149) (Subject)